Biotech entity
Every one of those 1 sits in a single category, clinical-trial. JAMA Internal Medicine is most often covered alongside 2024-2025 COVID-19 Vaccine, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention JAMA Internal Medicine, all published on June 28, 2026.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, clinical-trial. JAMA Internal Medicine is most often covered alongside 2024-2025 COVID-19 Vaccine, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention JAMA Internal Medicine, all published on June 28, 2026. Each carries 4 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 9 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JAMA Internal Medicine. Shared-story counts are live from our verified record — not editorial picks.
The 2024-2025 COVID vaccine reduced MACE by 37.7% in a large VA trial, with even greater benefits in high-risk subgroups, sparking biopharma interest in a cardiovascular indication for mRNA vaccines.
Source: wtag.iheart.com · wrno.iheart.com
JAMA Internal Medicine is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
